TY - JOUR
T1 - Glibenclamide plus metformin combination tablets are effective, convenient and well tolerated in the treatment of type 2 diabetes mellitus
AU - Derosa, Giuseppe
PY - 2006
Y1 - 2006
N2 - Combination therapy with an insulin-stimulating agent (i.e. glibenclamide [glyburide]) and an insulin-sensitising agent (i.e. metformin) is an optimal and rational therapeutic first- and second-line treatment in patients with type 2 diabetes mellitus. Single-tablet glibenclamide/metformin achieves better glycaemic control than monotherapy with either agent. The improved convenience of fixed-dose glibenclamide/metformin may improve patient compliance with treatment, thereby improving glycaemic control.
AB - Combination therapy with an insulin-stimulating agent (i.e. glibenclamide [glyburide]) and an insulin-sensitising agent (i.e. metformin) is an optimal and rational therapeutic first- and second-line treatment in patients with type 2 diabetes mellitus. Single-tablet glibenclamide/metformin achieves better glycaemic control than monotherapy with either agent. The improved convenience of fixed-dose glibenclamide/metformin may improve patient compliance with treatment, thereby improving glycaemic control.
UR - http://www.scopus.com/inward/record.url?scp=33745986054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745986054&partnerID=8YFLogxK
U2 - 10.2165/00042310-200622080-00001
DO - 10.2165/00042310-200622080-00001
M3 - Article
AN - SCOPUS:33745986054
SN - 1172-0360
VL - 22
SP - 1
EP - 6
JO - Drugs and Therapy Perspectives
JF - Drugs and Therapy Perspectives
IS - 8
ER -